Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: Findings from the EUCLID randomized controlled trial

Diabetes

Volumn 47, Issue 9, 1998, Pages 1507-1511

  Penno, Guiseppe ^a   Chaturvedi, Nish ^d   Talmud, Philippa J ^c   Cotroneo, Patricia ^b   Manto, Andrea ^b   Nannipieri, Monica ^a   Luong, Le Ahn ^c   Fuller, John H ^d  

^a Cattedra di Malat Metaboliche E D   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c Rayne Institute

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG EFFECT; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION;

EID: 0031678591     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.47.9.1507     Document Type: Article

References (30)

1. Rossing P, Rossing K, Jacobsen P, Parving H-H: Unchanged incidence of diabetic nephropathy in IDDM patients. Diabetes 44:7:19-743, 1995
2. Quinn M, Angelico MC, Warram JH, Krolewski AS: Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 39:940-945, 1996
3. Winkelmann BR, Nauck M, Klein B, Russ AP, Bohm BO, Siekmeier R, Ihnken K, Verho M, Gross W, Marz W: Deletion polymorphism of the angiotensin 1-converting enzyme gene is associated with increased plasma angiotensin-converting-enzyme activity, but not with increased risk of myocardial infarction and coronary artery disease. Ann Intern Med:125:19-25, 1996
4. Marre M, Bernadet P, Gallois Y, Savagner F, Guyene T-T, Hallab M, Cambien F, Passa P, Alhenc-Gelas F: Relationships between angiotensin I-converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes 43:384-388, 1994
5. Tarnow L, Cambien F, Rossing P, Nielsen FS, Hansen BV, Lecert L, Poirier O, Danilov S, Parving HH: Lack of relationship between an insertion/deletion polymorphism in the angiotensin 1-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. Diabetes 44:489-494, 1995
6. Doria A, Warram JH, Krolewski AS: Genetic predisposition to diabetic nephropathy: evidence for a role of the angiotensin I-converting enzyme gene. Diabetes 43:690-695, 1994
7. Chowdhury TA, Dronsfield MJ, Kumar S, Gough SCL, Gibson SP, Khatoon A, MacDonald F, Rowe BR, Dunger DB, Dean JD, Davies SJ, Webber J, Smith PR, Mackin P, Marshall SM, Adu D, Morris PJM, Todd JA, Barnett AH, Boulton AJM, Bain SC: Examination of two genetic polymorphisms within the reninangiotensin system: no evidence for an association with nephropathy in IDDM. Diabetologia 39:1108-1114, 1996
8. Schmidt S, Schone N, Ritz E, the Diabetic Nephropathy Study Group: Association of ACE gene polymorphism and diabetic nephropathy. Kidney Int 47:1176-1181, 1995
9. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, the Collaborative Study Group: The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
10. The Microalbuminuria Captopril Study Group: Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia. 39:587-593, 1996
11. Yoshida H, Mitarai T, Kawamura T, Kitajima T, Miyazaki Y, Nagasawa R, Kawaguchi Y, Kubo H, Ichikawa I, Sakai O: Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 96:2162-2169, 1995
12. Moriyama T, Kitamura H, Ochi S, Izumi M, Yokoyama K, Yamauchi A, Ueda N, Kamada T, Imai E: Association of angiotensin I-converting enzyme gene polymorphism with susceptibility to antiproteinuric effect of angiotensin I-converting enzyme inhibitors in patients with proteinuria. J Am Soc Nephrol 6:1676-1678, 1995
13. Van Essen GG, Rensma PL, de Zeeuw D, Sluiter WJ, Scheffer WJ, Apperloo AJ, de Jong PE: Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy. Lancet 347:94-95, 1996
14. Parving HH, Jacobsen P, Tarnow L, Rossing P, Lecerf L, Poirer O, Cambien F: Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. BMJ 313:591-594, 1996
15. The EUCLID Study Group: Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 349:1787-1792, 1997
16. Medcalf E, Newman DJ, Gorman EG, Price CP: Rapid, robust method for measuring low concentrations of albumin in urine. Clin Chem 36:446-449, 1990
17. 1c. Clin Chem 39:663-606, 1993
18. Talmud P, Tybjaerg-Hansen A, Bhatnagar D, Mbewu A, Miller JP, Durrington P, Humphries S: Rapid screening for specific mutations in patients with a clinical diagnosis of familial hypercholesterolaemia. Atherosclerosis 89:137-141, 1991
19. Rigat B, Hubert CV, Alhene-Gelas F, Cambien F, Corvol P, Soubrier F: An insertion/deletion polymorphism in the angiontensin I-converting enzyme gene accounting for half the variance of scrum enzyme levels. J Clin Invest 86:1343-1346, 1090
20. O'Dell SD, Humphries SE, Day IN: Rapid methods for population-scale analysis for gene polymorphisms: the ACE gene as an example. Br Heart J 73:368-371, 1995
21. Woolf B: On estimating the relation between blood group and disease. Ann Hum Genet 19:251-253, 1955
22. Fujisawa T, Ikegami H, Kawaguchi Y, Hamada Y, Ueda H, Shintani M, Fukuda M, Ogihara T: Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia 41:47-53, 1998
23. Parving H-H, Tarnow L, Rossing P: The angioteasin-converting enzyme gene and its inhibition in diabetic nephropathy. Curr Opin Endocrinol 3:315-321, 1996
24. Bjorck S, Blohme G, Sylven C, Mulec H: Deletion insertion polymorphism of the angiotensin converting enzyme gene and progression of diabetic nephropathy. Nephrol Dial Transplant 12 (Suppl. 2):67-70, 1997
25. Kitamura H, Moriyama T, Izumi M, Yokoyama K, Yamauchi A, Ueda N, Kamada T, Imai E: Angiotensin I-converting enzyme insertion/deletion polymorphism: potential significance in nephrology. Kidney Int Suppl 55:S101-S103, 1996
26. Schmidt A, Haas M, Ylmaz N, Mayer G, Kiener MP, Barnas U, Arias I, Illievich A, Avinger M, Graninger W, Kaider A: Angiotensin convening enzyme polymorphism in patients with terminal renal failure. J Am Soc Nephrol 7:314-317, 1996
27. Yoshida H, Kon V, Ichikawa I: Polymorphisms of the renin-angiotensin system genes in progressive renal diseases. Kidney Int 50:732-744, 1996
28. Singer DRJ, Missouris CG, Jeffery S: Angiotensin converting enzyme gene polymorphism: what to do about all the confusion. Circulation 94:236-239, 1996
29. Costerousse O, Allegrini J, Lopez M, Alhenc-Gelas F: Angiotensin I converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T lymphocytes. Biochem J 290:33-40, 1993
30. Chaturvedi N, Sjolie A-K, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, Rogulja-Pepeonik Z, Fuller JH, the EUCLID Study Group: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 351:28-31, 1998